387 related articles for article (PubMed ID: 20035570)
21. Insights into the carcinogenic mode of action of arsenic.
Kligerman AD; Tennant AH
Toxicol Appl Pharmacol; 2007 Aug; 222(3):281-8. PubMed ID: 17118416
[TBL] [Abstract][Full Text] [Related]
22. Arsenic cancer risk posed to human health from tilapia consumption in Taiwan.
Liao CM; Shen HH; Lin TL; Chen SC; Chen CL; Hsu LI; Chen CJ
Ecotoxicol Environ Saf; 2008 May; 70(1):27-37. PubMed ID: 18068227
[TBL] [Abstract][Full Text] [Related]
23. A human PBPK/PD model to assess arsenic exposure risk through farmed tilapia consumption.
Ling MP; Liao CM
Bull Environ Contam Toxicol; 2009 Jul; 83(1):108-14. PubMed ID: 19452117
[TBL] [Abstract][Full Text] [Related]
24. Mode of action in relevance of rodent liver tumors to human cancer risk.
Holsapple MP; Pitot HC; Cohen SM; Boobis AR; Klaunig JE; Pastoor T; Dellarco VL; Dragan YP
Toxicol Sci; 2006 Jan; 89(1):51-6. PubMed ID: 16221960
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the carcinogenicity of inorganic arsenic.
Cohen SM; Arnold LL; Beck BD; Lewis AS; Eldan M
Crit Rev Toxicol; 2013 Oct; 43(9):711-52. PubMed ID: 24040994
[TBL] [Abstract][Full Text] [Related]
26. Postulated carbon tetrachloride mode of action: a review.
Manibusan MK; Odin M; Eastmond DA
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(3):185-209. PubMed ID: 17763046
[TBL] [Abstract][Full Text] [Related]
27. Workshop overview: arsenic research and risk assessment.
Sams R; Wolf DC; Ramasamy S; Ohanian E; Chen J; Lowit A
Toxicol Appl Pharmacol; 2007 Aug; 222(3):245-51. PubMed ID: 17336359
[TBL] [Abstract][Full Text] [Related]
28. Dynamical coupling of PBPK/PD and AUC-based toxicity models for arsenic in tilapia Oreochromis mossambicus from blackfoot disease area in Taiwan.
Liao CM; Liang HM; Chen BC; Singh S; Tsai JW; Chou YH; Lin WT
Environ Pollut; 2005 May; 135(2):221-33. PubMed ID: 15734582
[TBL] [Abstract][Full Text] [Related]
29. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
[TBL] [Abstract][Full Text] [Related]
30. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
31. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
[TBL] [Abstract][Full Text] [Related]
32. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
33. Implications of arsenic genotoxicity for dose response of carcinogenic effects.
Rudel R; Slayton TM; Beck BD
Regul Toxicol Pharmacol; 1996 Apr; 23(2):87-105. PubMed ID: 8661328
[TBL] [Abstract][Full Text] [Related]
34. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
Clewell HJ; Gentry PR; Gearhart JM
J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
[TBL] [Abstract][Full Text] [Related]
35. Trichloroethylene and cancer: epidemiologic evidence.
Scott CS; Cogliano VJ
Environ Health Perspect; 2000 May; 108 Suppl 2():159-60. PubMed ID: 10807549
[TBL] [Abstract][Full Text] [Related]
36. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
Bogen KT; Gold LS
Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
[TBL] [Abstract][Full Text] [Related]
37. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
[TBL] [Abstract][Full Text] [Related]
38. Evidence against the nuclear in situ binding of arsenicals--oxidative stress theory of arsenic carcinogenesis.
Kitchin KT; Wallace K
Toxicol Appl Pharmacol; 2008 Oct; 232(2):252-7. PubMed ID: 18671993
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide analysis of BEAS-2B cells exposed to trivalent arsenicals and dimethylthioarsinic acid.
Chilakapati J; Wallace K; Ren H; Fricke M; Bailey K; Ward W; Creed J; Kitchin K
Toxicology; 2010 Jan; 268(1-2):31-9. PubMed ID: 19945496
[TBL] [Abstract][Full Text] [Related]
40. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
Gaylor DW; Swirsky Gold L
Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
